SETD2, a histone methyltransferase that functions as a tumor suppressor, is mutated in a variety of human cancers [122,123,124,125]; however, somatic SETD2 mutations occur in <2% of human osteosarcoma samples [126]. This evidence concerns the gene SETD2 and neoplasm.